CLDXCelldex Therapeutics, Inc.

$2B

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0-100.0% YoY

Gross Profit

$0

Operating Income

-$74M

Net Income

-$67M

EPS (Diluted)

$-1.01

QoQ Revenue Growth

-100.0%

Cash Flow

Operating Cash Flow

-$49M

Free Cash Flow

-$49M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$648M

Total Liabilities

$50M

Stockholders' Equity

$598M

Cash & Equivalents

$36M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$3M	-100.0%
Gross Profit	$0	$3M	-100.0%
Operating Income	-$74M	-$52M	-41.2%
Net Income	-$67M	-$42M	-59.2%

Revenue Segments

Grant

$1M96%

Service

$57,0004%

CLDX Q3 2025 Earnings — Celldex Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena